2024 Poster Presentations

P01: High-Throughput Screen to Identify and Optimize NOT Gate Receptors for Cell Therapy, Presented by Tanveer G., A2 Biotherapeutics

P02: Designing T-Cell Engagers with High Potency and Low Cytokine Release, Presented by Raffi T., AbCellera

P03: Directed Evolution of Existing Biologics for Novel Target Specificity, Affinity, and Local Environment, Presented by Hiep T., Abzyme Therapeutics

P04: Primary Human Immune Cell Assays for the Evaluation of New Immuno-Oncology Therapies, Presented by Robert B., Antibody Analytics

P05: Quantification of the Antigen Density Activation Threshold for Targeted Immunotherapeutics, Presented by Lewis C., Antibody Analytics

P06: Comparative Analysis: Responses to Immunotherapy, Standard-of-Care Treatment and Combined Therapy in MC38 Murine Colon Cancer, Presented by Linh N., Aragen Bioscience

P07: Development of High Throughput Single-B Cell Antibody Discovery Platform, Presented by Huanyi Y., Biointron Biological, Inc.

P08: A Proven and Reliable Alpaca VHH Antibody Discovery Platform, Presented by Haoming Z., Biointron Biological, Inc.

P09: nELISA High-Throughput Protein Profiling Captures Variability Across Cell Donors and Perturbations - Implications for Cell Therapy, Presented by Eric M. Nomic Bio

P10: Analytical Methods to Assess Critical Quality Attribute in mRNA-LNP Modality, Presented by Ye G., Crystal Pharmatech

P11: Rapid and Efficient Genome Editing for Human Primary T-Cells, Presented by Daniel K., EditCo Bio

P12: Generation of Immunocytokine Capable of Transforming Intratumoral Tregs into Fragile Phenotype Without Altering Systemic Tregs, Presented by Ellen W., Immunowake, Inc.

P13: Functional In Vitro Peptide Assay with Human Primary Cells for Immuno-Oncology Cancer Vaccine Evaluation, Presented by Martijn V., ImmunXperts, a Q2 Solutions Company

P14: High Throughput, High Resolution Epitope Mapping to Advance Cancer Immunotherapy Through Precision Targeting, Presented by Faraz C., Immuto Scientific

P15: Understanding the Interactions Between Colon Cancer Epithelial and Mast Cells in the Promotion of BRAF Mutant Colorectal Cancer, Presented by Rosie L., Indiana University

P16: Preclinical Safety Assessment for Specificity of Biotherapeutics Using the Membrane Proteome Array, Presented by Ileine S., Integral Molecular

P17: LP-184, a Novel Acylfulvene, Sensitizes Immuno-Refractory Triple Negative Breast Cancers (TNBCs) To Anti-PD1 Therapy by Affecting the Tumor Microenvironment, Presented by Aditya K., Lantern Pharma, Inc.

P18: Utilizing RNA Devices to Control PD-1 Gene Expression in Mammalian Cells for Cancer Immunotherapy, Presented by Vibha D., National Institutes of Health, National Cancer Institute

P19: PhaseX (Patient-derived Hydrogel-ASsisted EXplants): Unveiling the Biomarkers in Immune Checkpoint Blockade for HNSCC, Presented by Kanishka F., National University of Singapore

P20: Fully Human Heavy Chain Only Antibodies to BCMA Identified by NonaCarFx™ Platform, Presented by Jeffrey W., Nona Biosciences

P21: Discovery of T-Cell Receptor Mimic Antibody Derived T-Cell Engager, Presented by Musheng B., Nona Biosciences

P22: Preclinical Examination of EGFR Tumor-Targeted CD28-Bispecific Antibodies in Combination with PD-1 Checkpoint Inhibitor, Presented by Jacquelynn G., Regeneron Pharmaceuticals

P23: Investigating Lymphatic Disorders, Malignancies and Naturopathic Management, Presented by David J., Sonoran University of Health Sciences

P24: Current Immunotherapy Treatments of Primary Breast Cancer Subtypes, Presented by Savannah B., University of North Dakota

P25: Endothelial PD-L1 Critically Impacts NSCLC Progression, Presented by Lisa B., VIB-KU Leuven

P26: Purification of CAR-Expressing Cells Reveals Impact of Untransduced Cells in CAR-T Cell Drug Product, Presented by Daniel G., Vor Bio

P27: Enabling Research Tools for αβ and γδ T Cell-Based Immunotherapy, Presented by Zachary W., BPS Bioscience

Additional Virtual Posters

V1: CART – T Cells Therapy in the Treatment of Glioblastoma – What Stage Are We At?, Presented by Ewelina J., Cardinal Stefan Wyszynski University

V2: The Role of Hypoxia in Glioblastoma Development and the Possibility of Applying Knowledge to New Therapies - What Do We Know?, Presented by Ewelina J., Cardinal Stefan Wyszynski University

V3: The Role of Inflammasomes in the Pathophysiology of Glioblastoma, Presented by Ewelina J., Cardinal Stefan Wyszynski University

V4: Targeting Murine Metastatic Cancers with Adjuvanted Peptide Vaccines, Presented by Sanchari P., Gothenburg University